More research into CNTF treatment required

Article

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

Dr Jacque L. Duncan from the Beckman Vision Center, School of Medicine, University of California, San Francisco, California, USA, led a study group in the examination of the cone photoreceptor structure and function of the 2 patients with retinitis pigmentosa and 1 patient with usher syndrome.

All patients participated in a phase II clinical trial and were treated with sustained-release CNTF delivered by an encapsulated cell technology implant in one eye and sham surgery in the other. The outcome measures were obtained using AOSLO.

The results show that outer retinal layers were significantly thicker in CNTF treated eyes than the sham-treated eyes. The findings demonstrated there were no significant changes in VA, visual field sensitivity or ERG responses. AOSLO is a sensitive way to measure disease progression and reactions to treatment in patients. A larger study is required to determine the effect of CNTF treatment in inherited retinal degenerations.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.